These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20524319)

  • 21. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
    Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
    Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
    Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J
    Clin Transpl; 2009; ():351-8. PubMed ID: 20527073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.
    Lonze BE; Dagher NN; Simpkins CE; Singer AL; Segev DL; Zachary AA; Montgomery RA
    Clin Transpl; 2009; ():377-84. PubMed ID: 20524301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A summary of bortezomib use in transplantation across 29 centers.
    Everly MJ
    Clin Transpl; 2009; ():323-37. PubMed ID: 20524294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
    Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
    Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
    Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
    J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment with bortezomib of a refractory humoral rejection of the intestine after multivisceral transplantation.
    Island ER; Gonzalez-Pinto IM; Tsai HL; Ruiz P; Tryphonopoulos P; Gonzalez ML; Solano JP; Rossique M; Selvaggi G; Tekin A; Smith LJ; Tzakis AG
    Clin Transpl; 2009; ():465-9. PubMed ID: 20524316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abrogation of antibodies improves outcome of renal transplantation.
    Trivedi HL; Vanikar AV; Gumber MR; Patel HV; Shah PR; Kute VB
    Transplant Proc; 2012 Jan; 44(1):241-7. PubMed ID: 22310623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
    Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
    Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib is effective to treat acute humoral rejection after liver transplantation.
    Lee CF; Eldeen FZ; Chan KM; Wu TH; Soong RS; Wu TJ; Chou HS; Lee WC
    Transplant Proc; 2012 Mar; 44(2):529-31. PubMed ID: 22410063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib: a new player in pre- and post-transplant desensitization?
    Lemy A; Toungouz M; Abramowicz D
    Nephrol Dial Transplant; 2010 Nov; 25(11):3480-9. PubMed ID: 20826741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib for refractory antibody-mediated cardiac allograft rejection.
    Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES
    Clin Transpl; 2009; ():475-8. PubMed ID: 20524318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
    Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M
    Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
    Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
    Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intensive plasmapheresis and intravenous immunoglobulin for treatment of antibody-mediated rejection after kidney transplant.
    Ruangkanchanasetr P; Satirapoj B; Termmathurapoj S; Namkhanisorn K; Suaywan K; Nimkietkajorn V; Luesutthiviboon L
    Exp Clin Transplant; 2014 Aug; 12(4):328-33. PubMed ID: 25095710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteasome inhibition for recipient desensitization? A report of two sensitized kidney transplant candidates subjected to bortezomib treatment.
    Wahrmann M; Haidinger M; Drach J; Geyeregger R; Kikić Z; Raab R; Säemann MD; Böhmig GA
    Clin Transpl; 2009; ():415-20. PubMed ID: 20524307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
    Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy.
    Stuckey LJ; Kamoun M; Wadhwa A; Samaniego M; Bartos C; Berry J; Mahidhara R; Chang AC; Chan KM
    Clin Transpl; 2009; ():471-4. PubMed ID: 20524317
    [No Abstract]   [Full Text] [Related]  

  • 40. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
    Al Meshari K
    Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.